South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, March 21, 2025
1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	-	Brandi Tackett, PharmD	X
Bill Ladwig, RPh	X	Deidra Van Gilder, PharmD, Chair	X
Kelley Oehlke, PharmD	-	Clarissa Barnes, MD, DSS Staff	X
Lenny Petrik, PharmD	-	Mike Jockheck, DSS Staff	X
Heather Preuss, MD	-	Taylor Koerner, DSS Staff	X
Matthew Stanley, DO	X		

Administrative Business

Van Gilder called the meeting to order at 1:02 pm. The minutes of the September meeting were presented since the December meeting was canceled. Stanley made a motion to approve. Ladwig seconded the motion. The motion to approve the minutes was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from October 1, 2024, to December 21, 2024. A total of 3,837 PAs were reviewed of which 112 requests (2.9%) were received via telephone, 136 requests (3.5%) were received via fax, 1,434 requests (37.4%) were reviewed electronically, and 2,155 requests (56.2%) were received via ePA. There was a 2.7% increase in PAs received compared to the previous quarter. There was a 11% increase in number of appeals.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from October 1, 2024, to December 21, 2024. The top five therapeutic classes based on paid amount were atypical antipsychotics, incretin mimetics, interleukin-mediated agents, tumor necrosis factor inhibitors, and antineoplastic agents. These top 15 therapeutic classes comprise 16.6 % of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid constitute 9% of total claims. Ladwig asked the significance of the bolded drugs. These are a combined total of different drug formulations which the committee had requested several years ago.

Old Business

Opioid Update

The committee reviewed opioid outcomes compared to the previous quarter from the opioid initiatives. There was an increase in opioid utilization and utilizers during 4Q2024 with corresponding increase in total eligibility and utilizers. The average MME/day/utilizer stayed steady. Ladwig commented if members labeled as “shoppers” within the poly-prescribers may be within same clinic/practice. Members could be labeled “shoppers” if seen by different prescribers in the same clinic/practice.

Review of PA forms & criteria
The committee reviewed all PA criteria currently in effect. Jockheck said he reviewed the current list of PAs and have some potential removals such as Viibryd since it is available as generic. Van Gilder and Stanley both agreed.

Van Gilder asked for public comment. Jasmin Inman, pharmacist at Teva Pharmaceuticals, provided public comment on new headache guidelines for CGRPs. Van Gilder provided comment on commercial plan criteria. Tackett inquired on the process of how clinical treatment/standard guidelines are made to PA criteria. Jockheck replied indications are updated timely. Some treatment guidelines are brought to the committee for review. The committee can also provide input if practice guidelines are outdated.

After discussion, Van Gilder motioned to accept the PAs with changes discussed. Van Gilder inquired if there was any public testimony. Jasmine Inman provided public comment. Committee approved PAs.

New Business

Daybue review
Daybue clinical information was presented for review; including Baack's input on supporting State A's PA criteria with the inclusion of an endocrinologist and prescriber attestation that patient does not have other neurological problems. Mandi Champ, pharmacist with medical affairs from Acadia, provided public comment. Stanley supported Baack's input and made the motion to adopt the discussed PA to Daybue. Ladwig seconded the motion. The motion was approved unanimously.

Dupixent
Dupixent new indication information was presented for review. Committee discussed potential PA criteria for chronic obstructive pulmonary disease (COPD). Van Gilder inquired if there was any public comment. There were none. Stanley made the motion to adopt State A criteria with minor changes. Ladwig seconded the motion. The motion was approved unanimously.

Fintepla
Fintepla clinical information was presented for review. Committee discussed potential PA criteria. VanGilder was in favor of adding to PA with trial of Epidiolex first. Kierra Brown, pharmacist with medical outcomes from UCB, provided public comment. Brent Fushimi, medical channel management from UCB, provided public comment. Van Gilder made a motion to adopt State C PA criteria with minor changes. Ladwig seconded the motion. The motion was approved unanimously.

Voquezna
Voquezna clinical information was presented for review. Van Gilder stated step therapy is warranted for this drug. Van Gilder inquired if there was any public comment. There were none. Van Gilder made a motion to adopt State C PA criteria for Voquenza. Tackett seconded the motion. The motion was approved unanimously. Ladwig requested to review Voquezna Dual and Triple pack utilization for H. Pylori in one year.

Adjournment
The next meeting is scheduled on June 20, 2025. The September meeting is tentatively scheduled for September 26, 2025. All motioned and were in favor of adjourning the meeting. The meeting adjourned at 2:18 pm CT.